Search

Displaying results 2361 - 2370 of 10000 in total
  1. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [A182177] Benzhydrocodone is indicated for use in the short-term management of pain. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

  2. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.

  3. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    zone lymphoma in selected patients. … [L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure

  4. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain … [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]

  5. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

  6. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51389] It is also being investigated in amyotrophic lateral sclerosis (ALS) [A264414, A264429] and inclusion body myositis.[A264419] … [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).

    Synonyms: 3-PYRIDINECARBOXIMIDOYL CHLORIDE, N-((2R)-2-HYDROXY-3-(1-PIPERIDINYL)PROPOXY), 1-OXIDE, N-[(2R)-2-Hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxide
  7. Drug

    Kaolin

    go.drugbank.com/drugs/DB01575
    Approved

    Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. … Kaolin is a layered silicate mineral.

    Mixtures: Pranicura IIProducts: W Lab ALL CLEAR MINT PACK
  8. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.

    Categories: Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor
  9. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  10. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … suitable for use in patients with pre-existing cardiovascular disorders.